• Home
  • Practice Focus
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
    • How I Do It
    • TRIO Best Practices
  • Business of Medicine
    • Health Policy
    • Legal Matters
    • Practice Management
    • Tech Talk
    • AI
  • Literature Reviews
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Career
    • Medical Education
    • Professional Development
    • Resident Focus
  • ENT Perspectives
    • ENT Expressions
    • Everyday Ethics
    • From TRIO
    • The Great Debate
    • Letter From the Editor
    • Rx: Wellness
    • The Voice
    • Viewpoint
  • TRIO Resources
    • Triological Society
    • The Laryngoscope
    • Laryngoscope Investigative Otolaryngology
    • TRIO Combined Sections Meetings
    • COSM
    • Related Otolaryngology Events
  • Search

New Paradigms Emerging in Diagnosis, Management of Thyroid Cancer

by John Austin • December 1, 2006

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version

BRAF has been identified as the most prevalent of the mutations identified in papillary thyroid cancer.

You Might Also Like

  • Management Issues in Recurrent and Metastatic Thyroid Cancer
  • New Evidence-Based Guidelines on Thyroid Cancer
  • Shifting Paradigms in Thyroid Cancer Follow-Up
  • Study Raises Concern over Imaging after Thyroid Cancer
Explore This Issue
December 2006

This kind of worries me, because if BRAF is a marker of aggressive behavior, then you would expect that a large majority of our patients from whom samples were obtained, are likely to go on to have bad aggressive disease clinically, and I’m not sure this is necessarily true, Dr. Ezzat said. I would emphasize that on the aspirates, you can do RET/PTC rearrangements and you can do BRAF point mutations. And if you do these two and combine it with morphology, at least as of 2006, you’ve got it pretty much nailed in terms of combining molecular diagnosis with morphology.

Dr. Ezzat said there are drugs available now that specifically inhibit BRAF and they have been shown in recent studies to actually inhibit tumor growth, indicating that if it is possible to target this pathway, it’s not just of diagnostic value, but potentially of therapeutic value.

What I’m worried about, however, is not so much the diagnosis of papillary cancer, but I’m worried about papillary cancer that is going to invade, potentially metastasize, and potentially have impact on morbidity and mortality in that patient, he said. I think that’s where our efforts really need to lie.

And it’s not just the thyroid cancer that researchers and clinicians need to be thinking about, Dr. Ezzat emphasized, but also the thyroid neighbors-the so-called stromal elements and the matrix outside.

It’s this neighborhood interaction between the cancer cell, the host, and its cellular environment that’s going to be absolutely crucial in teaching us how we’re going to stop cancer from being a small indolent malignancy to one that has the ability to invade and metastasize and cause a lot more clinically aggressive disease, he said.

Risk Stratification

Approximately 25,000 cases of thyroid cancer were diagnosed in the United States last year, with an expected 30,000 this year. Fortunately, most of the patients with thyroid cancer are going to do very well. But how do you identify those few patients who are going to do poorly?

We used to say thyroid cancer was a rare disease, but if you look at the actual number of thyroid cancer cases diagnosed, it’s really not much different than the number of Hodgkin’s disease, myeloma patients, and kidney cancers that are diagnosed throughout the United States, said R. Michael Tuttle, MD, an endocrinologist at Memorial Sloan-Kettering Cancer Center in New York. The numbers have actually more than doubled in women since the 1970s, from six per 100,000 women to 13 per 100,000, and those numbers are going to go up.

Pages: 1 2 3 4 5 6 7 | Single Page

Filed Under: Departments, Head and Neck, Practice Focus Tagged With: cancer, diagnosis, Imaging, outcomes, radiation, risk, surgery, thyroid cancer, treatmentIssue: December 2006

You Might Also Like:

  • Management Issues in Recurrent and Metastatic Thyroid Cancer
  • New Evidence-Based Guidelines on Thyroid Cancer
  • Shifting Paradigms in Thyroid Cancer Follow-Up
  • Study Raises Concern over Imaging after Thyroid Cancer

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

The Triological SocietyENTtoday is a publication of The Triological Society.

Polls

Would you choose a concierge physician as your PCP?

View Results

Loading ... Loading ...
  • Polls Archive

Top Articles for Residents

  • Applications Open for Resident Members of ENTtoday Edit Board
  • How To Provide Helpful Feedback To Residents
  • Call for Resident Bowl Questions
  • New Standardized Otolaryngology Curriculum Launching July 1 Should Be Valuable Resource For Physicians Around The World
  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Popular this Week
  • Most Popular
  • Most Recent
    • A Journey Through Pay Inequity: A Physician’s Firsthand Account

    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • Otolaryngologists Are Still Debating the Effectiveness of Tongue Tie Treatment

    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?

    • Shifting the Treatment Goalpost Toward Medical Management of Recurrent Respiratory Papillomatosis

    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?

    • Is Middle Ear Pressure Affected by Continuous Positive Airway Pressure Use?

    • Otolaryngologists Are Still Debating the Effectiveness of Tongue Tie Treatment

    • Complications for When Physicians Change a Maiden Name

    • Excitement Around Gene Therapy for Hearing Restoration
    • “Small” Acts of Kindness
    • How To: Endoscopic Total Maxillectomy Without Facial Skin Incision
    • Science Communities Must Speak Out When Policies Threaten Health and Safety
    • Observation Most Cost-Effective in Addressing AECRS in Absence of Bacterial Infection

Follow Us

  • Contact Us
  • About Us
  • Advertise
  • The Triological Society
  • The Laryngoscope
  • Laryngoscope Investigative Otolaryngology
  • Privacy Policy
  • Terms of Use
  • Cookies

Wiley

Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1559-4939